Form 4: Adaptive Biotechnologies COO Executes Pre-Planned Stock Sales

Adaptive Biotechnologies' President and COO, Julie Rubinstein, executed pre-planned option exercises and subsequent stock sales totaling 57,180 shares.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (ADPT), reported multiple transactions involving the company's common stock.
• Transactions occurred on March 19, 2026, March 20, 2026, and March 23, 2026.
• Rubinstein acquired a total of 44,166 shares of common stock through option exercises at prices of $6.55 and $7.27 per share.
• Concurrently, Rubinstein disposed of a total of 57,180 shares of common stock through sales at weighted average prices ranging from $13.18 to $13.83 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025.
• Following these transactions, Rubinstein's direct beneficial ownership of common stock decreased to 481,906 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents routine insider activity under a pre-established trading plan, which is not typically indicative of new company-specific positive or negative developments.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading, reflecting good corporate governance practices.

Negatives

• The net effect of the transactions is a reduction in the reporting person's direct beneficial ownership of common stock, which some investors might interpret as a slight negative, despite the pre-planned nature.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions under Rule 10b5-1 plans are common practice for executives to manage personal liquidity and diversify holdings, aligning with standard corporate governance practices across various industries.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, so they are unlikely to have a significant direct impact on shareholder sentiment or the company's operational performance. The reduction in insider ownership is minor in the context of total shares outstanding.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, Rule 10b5-1 Plan, Executive Compensation, Julie Rubinstein